Exhibit 3.4

                                 STATE OF NEVADA
                          ARTICLES OF AMENDMENT TO THE
                            ARTICLES OF INCORPORATION
                                       of
                           APPLIED DNA SCIENCES, INC.

     Pursuant to the provisions of NRS 78.385 and 78.390, the undersigned
corporation adopts the following Articles of Amendment to its Articles of
Incorporation:

     1. The name of the corporation is: APPLIED DNA SCIENCES, INC.

     2. On July 30, 2003, stockholders holding a majority of the voting power of
the corporation (58.9%), by written consent pursuant to NRS 78.320, adopted the
recommendation of the Board of Directors and amended Article IV of the Articles
of Incorporation to read as follows:

                                   ARTICLE IV

The aggregate number of shares which the corporation shall have authority to
issue is One Hundred Ten Million (110,000,000) shares, divided into:

     10,000,000 Preferred Shares, having a par value of one tenth of a cent
     ($0.001) per share, and

     100,000,000 Common Shares, having a par value of fifty cents ($0.50) per
     share.

A statement of the preferences, privileges, and restrictions granted to or
imposed upon the respective classes of shares or the holders thereof is as
follows:

     A. Preferred Shares. Prior to the issuance of any of the Preferred Shares,
the Board of Directors shall determine the number of Preferred Shares to then be
issued from the Ten Million (10,000,000) shares authorized, and such shares
shall constitute a series of the Preferred Shares. Such series shall have such
preferences, limitations, and relative rights as the Board of Directors shall
determine and such series shall be given a distinguishing designation. Each
share of a series shall have preferences, limitations, and relative rights
identical with those of all other shares of the same series. Except to the
extent otherwise provided in the Board of Directors' determination of a series,
the shares of such series shall have preferences, limitations, and relative
rights identical with all other series of the Preferred Shares. Preferred Shares
may have dividend or liquidation


rights, which are prior (superior or senior) to the dividend and liquidation
rights and preferences of the Common Shares and any other series of the
Preferred Shares. Also, any series of the Preferred Shares may have voting
rights.

     B. Common Shares. The terms of the 100,000,000 Common Shares of the
corporation shall be as follows:

         (1) Dividends. Whenever cash dividends upon the Preferred Shares of all
series thereof at the time outstanding, to the extent of the preference to which
such shares are entitled, shall have been paid in full for all past dividend
periods, or declared and set apart for payment, such dividends, payable in cash,
stock, or otherwise, as may be determined by the Board of Directors, may be
declared by the Board of Directors and paid from time to time to the holders of
the Common Shares out of the remaining net profits or surplus of the
corporation.

         (2) Liquidation. In the event of any liquidation, dissolution, or
winding up of the affairs of the corporation, whether voluntary or involuntary,
all assets and funds of the corporation remaining after the payment to the
holders of the Preferred Shares of all series thereof of the full amounts to
which they shall be entitled as hereinafter provided, shall be divided and
distributed among the holders of the Common Shares according to their respective
shares.

         (3) Voting rights. Each holder of a Common Share shall have one vote in
respect of each share of such stock held by him. There shall not be cumulative
voting.

     In witness thereof, the undersigned, for the purpose of amending the
Articles of Incorporation of corporation has caused this certificate to be
signed by its President and Secretary on this 30th day of July 2003.


                                    APPLIED DNA SCIENCES, INC.


                                    /s/  Larry Lee
                                    --------------
                                    Lawrence Lee, President and CEO